Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was

On Wednesday, the Food and Drug Administration’s approved mFlusiva, the first mRNA seasonal influenza vaccine ever licensed in this country. In June the agency’s own advisory committee voted unanimously that its benefits outweigh its risks in adults 50 to 64, then unanimously again for adults 65 and older. Nine independent experts, appointed by this government, could not produce a single vote against it.

Wednesday was also an anniversary. On Aug. 5, 2025, the Department of Health and Human Services killed 22 mRNA vaccine development projects worth roughly $500 million and ordered a halt to federal investment in the platform.

Read the rest…

Read More

Published

on

On Wednesday, the Food and Drug Administration’s approved mFlusiva, the first mRNA seasonal influenza vaccine ever licensed in this country. In June the agency’s own advisory committee voted unanimously that its benefits outweigh its risks in adults 50 to 64, then unanimously again for adults 65 and older. Nine independent experts, appointed by this government, could not produce a single vote against it.

Wednesday was also an anniversary. On Aug. 5, 2025, the Department of Health and Human Services killed 22 mRNA vaccine development projects worth roughly $500 million and ordered a halt to federal investment in the platform.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

Read More

Published

on

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

Read More

Continue Reading

Uncategorized

Braveheart pumps more life into biotech IPO market with $382M expected debut

Published

on

Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.

Continue Reading

Uncategorized

STAT+: Two FDA approvals — a new drug and a new vaccine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Again, a child dies in a gene therapy trial in China, and STAT has exclusive details. Also, we have encouraging fecal pill results for peanut allergy, and see biotech investor Greg Verdine notch a series of wins.

In other news, it’s been hot out! My backyard tortoise, Philbert, has been most irascible and taken to his fainting couch (cardboard box).

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Again, a child dies in a gene therapy trial in China, and STAT has exclusive details. Also, we have encouraging fecal pill results for peanut allergy, and see biotech investor Greg Verdine notch a series of wins.

In other news, it’s been hot out! My backyard tortoise, Philbert, has been most irascible and taken to his fainting couch (cardboard box).

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending